Turning tumors from cold to inflamed to improve immunotherapy response.
Cold tumors
Hot tumors
Immunotherapy
Inflamed tumors
Tumor microenvironment
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
06
01
2021
revised:
13
05
2021
accepted:
15
05
2021
pubmed:
17
10
2021
medline:
23
11
2021
entrez:
16
10
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors have revolutionized the treatment landscape for a number of cancers over the last few decades. Nevertheless, a majority of patients still do not benefit from these treatments. Such patient-specific lack of response can be predicted, in part, from the immune phenotypes present in the tumor microenvironment. We provide a perspective on options to reprogram the tumors and their microenvironment to increase the therapeutic efficacy of immunotherapies and expand their efficacy against cold tumors. Additionally, we review data from current preclinical and clinical trials aimed at testing the different therapeutic options in monotherapy or preferably in combination with checkpoint inhibitors.
Identifiants
pubmed: 34656019
pii: S0305-7372(21)00075-X
doi: 10.1016/j.ctrv.2021.102227
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102227Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.